AKTX
Akari Therapeutics, Plc
NASDAQ · Healthcare · Biotechnology · GB
$11.77
+8.58%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$22.92M
MomentumView details →
1D Return
+8.58%
YTD Return
−5.57%
RSI (14)
64.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.5x
Market Cap
$22.92M
RSI (14)
64.3
MomentumView details →
1D Return
+8.58%
YTD Return
−5.57%
SummaryUpdated Jun 1, 2026
Akari Therapeutics, Plc (NASDAQ:AKTX) is a clinical-stage biopharmaceutical company founded in 2014 and based in London, United Kingdom. The company specializes in developing advanced therapies targeting autoimmune and inflammatory diseases through complement system inhibition. Since its IPO in January 2014, Akari has focused its research and development efforts on creating treatments for rare and serious conditions where the complement system - a key component of the immune system - plays a destructive role. The company is currently in clinical development phases with its lead drug candidate and has not yet generated commercial revenue.
Similar companies
Latest newsMore news →
Akari Therapeutics announced that AKTX-101, its antibody-drug conjugate, demonstrated robust anti-tumor activity in preclinical urothelial cancer models, supporting its differentiated ADC strategy.18d agoAkari Therapeutics Plc reported a net loss of $4.8 million for Q2 2026, compared to a net loss of $1.9 million in Q2 2025, with research and development expenses rising to $2.1 million from $0.7 million year-over-year.23d ago